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Abstract 
PREECLAMPSIA: THE ROLES OF ACUTE INFLAMMATION AND 
INTRAUTERINE STRESS 
Preeclampsia (PE) is a severe, acute disease of pregnancy affecting 
approximately 8% of pregnant women after week 20 of gestation. PE is 
characterized by hypertension and renal damage reflected by proteinuria and has 
significant morbidity to both mother and fetus. Maternal symptoms range from 
headaches, nausea, edema, to visual changes, but once maternal symptoms 
present, damage to the fetus has begun. Mothers who progress untreated 
through the disease can also experience a condition called eclampsia 
characterized by seizure, coma, and, ultimately, death. PE-affected newborns 
experience features similar to prematurity—abnormal lung and renal 
development, intrauterine growth retardation (IUGR), and, possibly, fetal demise. 
Interestingly, it has been shown that exposure to PE in utero can lead to many 
developmental problems during the progeny’s life span. While intensive research 
has been dedicated to understanding the underlying pathogenesis of PE, no 
cause, predictive clinical test, nor definitive treatment has been discovered.  
Although many factors are presumed as causative for PE pathogenesis, literature 
has indicated that acute inflammation may play a role in the development of PE. 
One such inflammatory factor is C-reactive protein (CRP). CRP, although 
regarded as a non-specific innate immune factor, is found to be elevated in PE 
mothers prior to onset of symptoms. The presence could indicate that CRP may 
play a role in the development of PE pathology. Further, CRP binds to bacterial 
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membranes through phosphocholine residues to trigger complement and other 
innate immune responses.  
Similarly, phosphocholination is a cellular process wherein phosphocholine 
residues are added to biological molecules via an endoplasmic reticularly 
mediated enzyme, phosphocholine transferase. A recently identified neurally-
secreted placental peptide and known pathogenic factor of PE, Neurokinin B 
(NKB), is phosphocholinated. This post-translational phosphocholination is 
thought to increase stability and binding of NKB to its Gq coupled receptor, 
NK3R. It is thought that this post-translational modification is bound by CRP 
thereby creating a molecular complex to preferentially activate NK3R. 
In addition to investigating the pathogenic role of inflammation in PE, we are also 
curious as to how intrauterine expose to PE affects cardiovascular development 
in progeny. Previous literature has demonstrated that PE predisposes offspring 
to adult-onset hypertension; however, the mechanism of this fetal programing 
remains unknown. We hypothesize that hypertension in offspring exposed to PE 
in utero results via a two hit mechanism: 1) PE-related intrauterine stress induces 
epigenetic modifications in offspring, and 2) these modifications in the presence 
of environmental stressor lead to hypertension. Furthermore, we postulate that 
these epigenetic modifications are conserved across generations. Intrauterine 
epigenetic changes, specifically decreased global methylation of renal DNA and 
AT1R promoter, in offspring born to PE mothers are conserved across 
generations. When combined with an additional environmental stimulus, these 
changes result in hypertension. These finding posit novel mechanisms for the 
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etiology of hypertension and provide vital screening targets to assess the risk of 
hypertension in progeny.  
These two approaches to PE study combine investigation of the maternal PE 
insult and pathogenesis with the investigation of transgenerational hypertensive 
features to progeny, we posit a global view of PE study. We not only examine 
potential targets for therapeutics and preclinical diagnostic exams, we also 
provide a mechanism for transmission of hypertensive features through 
generations and the possibility for hypertensive risk assessment. 
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Background 
Preeclampsia (PE) is a very severe disease of pregnancy which affects 
approximately 10 million mothers per year worldwide. Characterized by 
hypertension and proteinuria during the mid-second trimester of pregnancy, PE 
can result in significant fetal developmental problems and maternal morbidity. 
Affected mothers can experience renal and cardiac morbidity as well as a risk for 
life-long hypertension. Uncontrolled PE symptoms can result in seizure, coma, 
and death. Fetal manifestations are varied and include features of prematurity, 
intrauterine growth restriction, cardiac and renal malformation, and neural 
developmental delay.  
Despite significant research efforts over the past decades to define the 
pathogenesis behind PE, no specific cause of the disease has been found. 
Further, due to the pleiotropic causes of PE, neither clinical test nor treatment 
has been found to halt disease pathogenesis apart from symptomatic treatment 
of the mother and delivery of the fetus at earliest stage of viability. There are 
thought to be many factors in the pathogenesis behind PE, further complicating 
its early detection and treatment. sFlt-1 and complement cascades, intrinsic 
vascular damage/malformation, and oxidative stress have all been previously 
posited to initiate features of PE in animal and human models. 
sFlt-1 and its Role in the Initiation and Positive Feedback Cycle in PE 
Soluble fms-like tyrosine kinase (sFlt-1) is an anti-angiogenic factor which 
regulates vascular formation during production of new vascular beds, as is seen 
1 
 
during placental formation. sFlt-1 is one of the most potent endogenous inhibitors 
of vascular endothelial growth factor and, thereby, inhibits placental growth factor 
signaling. sFlt-1 was first hypothesized as an initiator in PE after recombinant 
protein infusions in mouse models resulted in similar features found in clinical 
PE.1-3 Increases in sFlt-1 circulating levels have been found in women who have 
growth-restricted fetal births as well as placental insufficiency. Early findings by 
the Levine group demonstrated elevations of sFlt-1 in second and third trimester 
of pregnancies complicated by growth restriction and PE, however, more recent 
studies have also show elevations of sFlt-1 as many as five weeks prior to onset 
of PE.4 Evidence indicates that transcription and release in sFlt-1 is resultant 
from placental hypoxia and ischemia. The increases in this antiangiogenic factor 
result in a malicious cycle causing further placental damage. 
Current literature demonstrates that balance between pro- and anti-
angiogenic factors is crucial to proper placentation and fetal development. To 
abrogate placental damage, increases in sFlt-1 are coupled with an increase in 
pro-angiogenic placental growth factor (PlGF) in early placental growth stages. In 
PE, it has been demonstrated that this balance shifts toward anti-angiogenesis 
resulting in a decrease of placental growth.5, 6 The dysfunction of placental 
growth leads to further placental hypoxia and increasing release of sFlt-1. This 
malicious anti-angiogenic factor release cycle is thought to underlie the 
pathogenesis of PE. However, attempts to mitigate the effects sFlt-1 have not 
been demonstrated to halt the progression of PE symptomology.  
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Complement Cascades and PE 
 The complement cascade comprises more than 50 proteins and utilizes 3 
main pathways to protect against foreign pathogens—classical, alternative, and 
lectin pathways. The activation of the various pathways or development of split 
products within the pathway provides innate protection again microorganisms 
and assistance in the activation of intrinsic immunity. The activation of the 
complement cascade is regulated by inhibitors at various stages of each 
pathway. Both membrane and soluble inhibitors control activation at early and 
late stages of each pathway.7, 8 
 In pregnancy, the fetus and placenta represent foreign tissue. The 
maternal immune system functions to protect the feto-placental environment, 
however, the exact mechanism has never been elucidated. In the initial stage of 
pregnancy, apoptosis in the uterine wall results in decidual tissue suitable for 
implantation of the embryo. Activation of the adaptive immune system 
accompanies implantation, resulting in complement C3 activation to assist in 
invasion into the uterine decidua. Unique to pregnancy, decidual tissues secrete 
C1q, importnant for vascular formation at the decidual-embryonic interface.9, 10 
This is further shown in C1q-deficient mice, which demonstrate abnormal 
placentation and dysfunctional artery development within the implanted uterus. 
 Abnormal complement activation has been previously demonstrated to be 
important in the development of PE. Previous studies have demonstrated 
significant complement activation in PE compared to normal pregnancy 
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outcomes. Derzsy et al. reported that C3 is decreased in PE pregnancies while 
C3 split products and C5-C9 are increased, owing to greater complement 
activation within the feto-placental environment. Additionally, some studies have 
associated terminal complement components (C5-9) in pregnancies resulting in 
fetal growth restriction.8-11 
 Despite identification of complement’s role in PE, large scale studies have 
not confirmed the diminution of PE symptoms by commercial complement 
inhibitors. Case reports describe eculizumab, a C5 inhibitor, could provide 
symptomatic relief of PE symptoms. Treatment with this inhibitor has shown 
efficacy of complement inhibition in prolonging the pregnancy, lowering 
hypertension, and resolving HELLP syndrome in one case.8 Clinical treatment 
with this inhibitor is regarded as somewhat risky due to complement’s role in 
meningococci opsonization and the potential role complement has in bacteremia. 
While inhibition of C5 is safer than other complement component inhibition since 
it is not at the beginning of the complement cascade, safety of drug therapy in 
pregnancy must be well-elucidated prior to human subject trials.  
Vascular Damage and its Role in PE 
 Spiral artery formation during placentation is one of the most crucial steps 
in development of healthy fetuses. Normally, the process takes place over the 
first two trimesters in two stages—invasion into the decidua (as aforementioned) 
during the first trimester and myometrial invasion during the second trimester. 
Normal spiral artery formation is characterized by dilation during the second 
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trimester decreasing the velocity of flow into the placental bed. Failure to remodel 
the spiral arteries results in tonic constriction and elevated velocity of blood flow 
into the placenta. This elevated velocity results in placental damage, 
vacuolization, and shedding of the intrinsic trophoblastic tissue of the placenta. 
Damage to the placenta results in vasoactive cytokine release and an attempt 
repair of the damaged blood vessels.12-14 If remodeling of the spiral arteries fail, it 
is thought that the PE cascade can occur. 
 Beside placental damage in PE, another hallmark of this disease is renal 
damage resultant from glomerular dysfunction. Proper glomerular endothelial 
structure is integral to effective filtration and reabsorption within the kidney. Renal 
biopsies of women affected by PE show a few key features of damage—
endothelial edema, obliteration of the capillary spaces, and elimination of 
fenestrated endothelia. Interestingly, these hallmarks are also seen in other 
hypertensive disorders of pregnancy without proteinuria, indicating that this 
damage may not be intrinsically specific to PE. However, it is well-characterized 
that damage to the glomerulus causes renally-mediated hypertension.3, 11, 15 
Additionally, damage to glomerular endothelia is known to cause imbalances in 
the VEGF angiogenic cascade normally seen in PE. 
Reactive Oxygen Species Cascade in PE 
 Related to the vascular hypothesis of PE, reactive oxygen species and 
nitric oxide (NO) bioavailability are related to both PE and vasodilatation, 
essential in normal placental perfusion. It is well-known that hypoxic 
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environments, as found in PE hypoperfused placentas, leads to activation of 
proinflammatory cytokines and activation of NADPH oxidase. It has been 
reported that NADPH oxidase is much more sensitive in PE patients than normal 
pregnant women. NADPH oxidase produces reactive oxygen species (ROS) 
through the catalysis of available oxygen and NADPH, an energy transport 
molecule. ROS production leads to vascular dysfunction through intrinsic 
endothelial damage. Furthermore, uncontrolled ROS leads to imbalance of nitric 
oxide (NO) signaling, important for regulation of vascular tone. The uncoupling of 
NO signaling by ROS is essential to development of hypertension and failure to 
rectify ROS production can lead to uncontrolled PE.2, 16 
 Despite identification of this pathway and its probable role in PE, attempts 
to negate ROS production by antioxidants proved unsuccessful. Antioxidant 
supplementation trials by the Maternal-Fetal Medicine network showed that 
Vitamin C and E supplementation failed to reduce PE symptom onset in at-risk 
mothers. Examination of other important antioxidant pathways, superoxide 
dismutase, catalase, and glutathione peroxidase, all have been demonstrated to 
be decreased in PE mothers versus normal pregnant mothers. However, neither 
supplementation trial nor medication has been developed to stimulate these 
pathways. 
Role of Uterine Environment in Fetal Programming 
 As aforementioned, if untreated, PE has devastating effects on the 
mothers and fetuses. A growing body of evidence also investigates the role of 
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pregnancy-related stress and patterning effects on the fetus. It is hypothesized 
that outside of the known genetic effects on the fetus, the maternal uterine 
environment can developmentally pattern the fetus and predispose offspring to 
lifelong health problems. Data suggests that maternal uterine stress, obesity, and 
metabolic derangements can all have deleterious effects on the fetus including 
hypertension, cardiac disease, and metabolic pathway dysfunction. These 
patterning changes can occur on multiple levels—DNA methylation changes to 
alter genetic expression, RNA translation modifications, variations in hormone 
expression. These varied changes can all have deleterious effects within the 
developing organism. Moreover, epidemiologic evidence suggests that these 
changes can pass from generation of progeny to the next, affecting subsequent 
generations after initial insult.17-22 The mechanism behind the transgenerational 
passage of patterning features has not been thoroughly investigated. 
 The body of work presented here aims to investigate the central role of 
innate immunity in PE and propose a mechanism behind progeny patterning in 
the setting of pregnancy related stress.  
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Introduction 
Preeclampsia (PE) Symptomology and Diagnosis 
Preeclampsia (PE) is a serious disease of pregnancy affecting 
approximately 8% of all US pregnancies and accounts for 50,000 deaths 
worldwide. The key features of PE are hypertension and proteinuria after the 20th 
week of gestation. The increased monitoring and therapy of these women 
account for almost $70,000 in increased healthcare spending per case. More 
importantly, in spite of intensive research efforts and increased focus on 
prevention and treatment, neither definitive testing nor therapy has been found 
for PE. Currently, the only curative solution for PE symptoms is to deliver the 
fetus. PE presents significant acute and chronic risks for the mother—renal 
damage, cardiac damage, progression to seizure, coma, and death. 
Furthermore, PE also presents risk to fetuses exposed in utero—intrauterine 
growth restriction (IUGR), features of prematurity, abnormal heart and lung 
development—which predispose the fetus to cardiovascular risk later in life.23 
Therefore, understanding the mechanisms underlying PE is extremely important 
for early detection, as well as safe and effective therapy to treat this disease. 
In recent years, increased focus has aimed toward pre-symptomatic 
diagnosis of PE and prevention. Currently, in high-risk patients suspected of a 
PE diagnosis, clinicians may analyze a PE laboratory panel—complete blood 
count, blood urea nitrogen, creatinine, and liver function markers. Analyzed 
together, these markers are sensitive for suspected diagnosis. Recent studies 
indicate that inflammatory, placentally-derived, and immune biomarkers may 
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serve as potential factors in better screening and pre-symptomatic diagnosis. 
Thus, the focus of our study was to examine various implicated in the 
development of PE, as well as how PE is propagated through generations of 
people.  
Immune and Inflammatory Factors Underlie PE 
 Previous studies have implicated both autoimmune and inflammatory 
dysregulation as underlying the pathogenesis of PE. Over the past decade, 
literature has characterized autoimmunity as being fundamental in the 
pathogenesis of PE. The autoimmune factor, the activating autoantibody against 
the angiotensin II type I receptor (AT1-AA), has been isolated from PE patients 
and extensively characterized. Pathologic activation of the angiotensin II type I 
receptor (AT1R) has been shown to precipitate hypertension and renal damage 
in patients with this circulating antibody.10, 24-26 It is known that the renin-
angiotensin-aldosterone system (RAAS) must be tightly regulated to account for 
homeostatic blood pressure regulation. The presence of AT1-AA in the sera of 
PE patients is linked with pathologic activation of the RAAS, as well as 
derangement of blood pressure control mechanisms.  
 AT1-AA and the RAAS have been very well characterized in both human 
and mouse models. AT1-AA has been shown to bind the second extracellular 
loop of the AT1R, causing activation of this Gq-coupled receptor. Activation of 
this receptor initiates a cascade of calcium influx and secondary messaging 
signaling pathways within the cell. First characterized within the past decade, 
AT1-AA has been shown to correlate with PE severity, IUGR, placental ischemia 
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and insufficiency, and maternal morbidity. Moreover, AT1-AA is thought to lead to 
immune activation in both human and animal models. The reduced uterine 
perfusion pressure (RUPP) rat model has shown dysregulations in various 
proinflammatory cytokines—TNF-α, IL-6, IL-17, and CRP27-40—in the presence of 
AT1-AA. Furthermore, an adoptive transfer mouse model involving AT1-AA 
precipitates PE features in a pregnant murine system. The adoptive transfer 
model also precipitates other features common in PE patients, immunologic 
dysregulation. The presence of AT1-AA in the murine model also initiates a 
cascade of innate immune factors. Elevations of TNF-α and IL-6 primarily 
contribute to immunologic cascades and subsequent activation of the adaptive 
immune system. 
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Figure 1-1. Cascade of immune factors predispose PE.  
Research has demonstrated that IL-6 is a potent signaling factor for the 
transcription and release of CRP. Furthermore, pathologic activation of the AT1R 
by AT1-AA involves TNF-α signaling and activation of the innate inflammatory 
signaling cascade. While this pathway has been well-elucidated in previous work, 
we encounter a significant knowledge gap with the action of CRP. The presence 
of CRP in this cascade presents a novel question in the pathogenesis of PE. 
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Research has demonstrated AT1-AA and TNF-a as integral in the 
pathogenesis of key features of PE—hypertension, renal damage, and IUGR. 
These elevations also can precipitate a concurrent elevation of IL-6, a key 
initiator of CRP transcription and release. A significant knowledge gap exists in 
describing how CRP is involved in this inflammatory cascade and how it 
functions in the pathogenesis of PE. 
C-Reactive Protein (CRP) and its role in PE 
 Innate immune factors have long been postulated to be important in the 
pathogenesis of PE. One immune factor, CRP, has been disputed as contributory 
to PE pathology. CRP is a pentamer joined by noncovalent bond, with each 
monomer sized approximately 26 kDa. Viewed axially, CRP has two faces which 
assist in its innate immune actions. One side binds with bacterial membranes, 
damaged cell membranes, foreign pathogens, while the other side communicates 
with complement proteins to assist in the opsonization process. Activation of the 
complement pathways assist in subsequent activation of adaptive immune 
components.41-43 Furthermore, one of the main stimuli for synthesis and release, 
IL-6, is involved in signaling many other proinflammatory factors. Because of its 
nonspecific actions, CRP was not assumed to be important in PE pathogenesis.  
 Although initially assumed to be uninvolved in PE pathogenesis, CRP has 
recently been implicated as a pathogenic factor in many different diseases. 
Although mainly synthesized and secreted from hepatocytes, CRP elevations are 
linked to elevated cardiovascular risk and likely lead to disease pathogenesis via 
inappropriately targeting host tissues or recruiting immune cells to sites of injury. 
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Persistent elevations in CRP are associated with atherosclerosis secondary to 
intimal arterial damage.42-46 This kind of damage can occur by foam cell 
formation and exacerbation of an atherosclerotic lesion. Of importance, CRP 
elevations have also been noted in PE patients and linked to symptom 
severity.47-49 While studies are conflicted about the elevation of CRP early during 
pregnancy course,50-53 some have indicated elevations of CRP prior to the onset 
of PE.54, 55 This indicates that CRP may serve as a predictive biomarker of PE 
onset. However, the functional role of CRP in the pathogenesis of PE remains a 
mystery.  
Role of the Kinin Signaling Pathway in PE 
 Previous research behind the pathogenesis of PE has led to the 
hypothesis that this disease is one involving many factors and pathways. 
Recently, the kinin signaling pathway has also been thought to be involved in 
disease progression. One member of this pathway, neurokinin B (NKB), was 
shown to be elevated in PE patient’s sera in late diagnoses of PE. NKB is a short 
13-residue neurally secreted peptide.56-58 Earlier studies on the action of NKB 
have identified three primary receptors which the peptide is able to bind—the 
neurokinin 1 (NK1R), neurokinin 2 (NK2R), and neurokinin 3 (NK3R) receptor. 
These three receptors have shown to produce pleiotropic actions depending on 
the tissue in which they are most prevalent. Significantly, NK3R activation on 
vascular beds can produce vasoconstriction and increased systemic 
resistance.56, 59 However, the actions of NKB on other receptors may counter the 
actions at the NK3R.  
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 To increase specificity and preferential action at the NK3R, one study 
investigated a possible mechanism to explain specific activation of the NK3R. 
Posttranslational modification (PTM) is an indispensable mechanism to regulate 
cellular and systemic functions. Modifications such as phosphorylation, 
glycosylation, ubiqutination, methylation, and acetylation are common and 
necessary PTM to regulate cellular pathways. These modifications are necessary 
to amplify or diminish the activity of a biological molecule or alter ligand-receptor 
binding. One such PTM, phosphocholination, is thought to be involved in NKB 
preferential activation of the NK3R.60 Interestingly, phosphocholinated NKB is 
thought to only be found in two tissues, placenta and testis, indicating its possible 
relevance to our study. Furthermore, specific activation of the NK3R is thought to 
be important for the development of hypertension in pregnancy via activation of 
the Gq-coupled transmembrane NK3R.61 
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Materials and Methods 
Human Subjects 
Human materials were acquired from normal pregnant women (NT) and 
preeclamptic patients (PE) admitted to Memorial Hermann Hospital which were 
identified by the Obstetrics and Gynecology faculty of the University of Texas 
Medical School at Houston, or from nulligravid women (NG) with no significant 
past medical history in a gynecologic clinical setting.  Patients were stratified to 
diagnoses of severe preeclampsia, mild preeclampsia, or normotensive based on 
blood pressure criteria set forth by the National High Blood Pressure Education 
Working Group (2000). Patients were classified as preeclamptic based on the 
presence of systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 
mmHg and presence of proteinuria ≥ 300 mg/24 hr. Further stratification for 
severe PE was based on the presence of systolic blood pressure ≥ 160 mmHg or 
diastolic ≥ 110 mmHg (NHBPEWG; 2000). Patients identified by research staff 
were consented and enrolled in a collection study. Patient blood was collected in 
EDTA and silicone collection tubes. The blood inside the silicone tubes was 
allowed to clot, meanwhile, the EDTA tubes were centrifuged at 2500xg for 15 
minutes. After clotting, the silicon tubes were then centrifuged at 2500xg for 15 
minutes. All plasma and sera was collected and stored at -80°C. The research 
protocols, consent forms were approved by the University of Texas Committee 
for the Protection of Human Subjects (HSC-MS-04-384). Human subject data are 
summarized and included in Table 1. 
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 Table 1. Patient Characteristics 
  NG NT PE 
Age 26.2 ± 5.6 yr 30.4 ± 7.35 yr 27.2 ± 6.66 yr 
N 
Racial 
Distribution (%) 
21 15 15 
Caucasian 48 33 27 
African American 10 40 47 
Hispanic 33 27 19 
Other 9 0 7 
BMI 24.9 ± 5.6 31.352 ± 8.38 39.305 ± 8.48 
Gestational Age NA 38.4 ± 0.99 wk 36.3 ± 2.42 wk 
Systolic Max 118.0 ± 11 mmHg 124.1 ± 11.68 
mmHg 
163.2 ± 25.99 
mmHg 
Diastolic Max 75.0 ± 7 mmHg 72.4 ± 9.75 mmHg 100.3 ± 22.01 
mmHg 
Proteinuria <300 mg/dL <300 mg/dL >300 mg/dL 
Fetus Weight NA 3200.4 + 474.5 g 2140.5 ± 
867.86 g 
*NG, nulligravid; NT, normotensive; PE, preeclamptic; BMI, body mass index. 
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Animal Models 
Pregnant C57BL/6 mice were obtained from Harlan Laboratories on 
embryonic day 13 of gestation (E13) and injected with 75 μg/mL of recombinant 
CRP (R&D/Tocris, Bristol, UK) on E13/E14. Eight week old nonpregnant mice 
were also injected with 75 μg/mL of recombinant CRP.  In addition to CRP, 
pharmacologic and siRNA knockdowns of the kinin system were used in the 
model. The specific NK3R antagonist SB222200 (2.5 μM; R&D/Tocris, Bristol, 
UK) was coinjected with CRP. All injection volumes were normalized to 100 μL 
total volume. Alternatively, an in vivo siRNA knockdown method (Altogen 
Biosystems, Las Vegas, NV) using nanoparticles was used to surround ~150 μg 
of specific NK3R and/or PCT siRNA constructs (Sigma; Santa Cruz Biosciences, 
St. Louis, MO; Dallas, TX, respectively). siRNA constructs were validated by 
companies in terms of knockdown efficiency and multiple constructs were pooled 
to achieve the most efficient knockdown strategy. Injections were prepared w/v 
5% glucose to 100 μL volume according to the Altogen protocol. Mice were 
injected IV via retro-orbital injection methodology with ≤ 100 μL injection volume 
per inferior orbital vein. Mice husbandry care was undertaken by Center for 
Laboratory Animal Medicine and Care (CLAMC) and Animal Welfare Protocol UT 
AWC-11-073/14-090.  
Measurement of Blood Pressure and Proteinuria in Mice 
The systolic blood pressure of all mice was measured at the same time 
daily by a carotid catheter-calibrated tail-cuff system  (CODA, Kent Scientific, 
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Torrington, CT), and the mice were kept warm using a warming pad (AD 
Instruments Co, Colorado Springs, CO). Blood pressure was recorded and 
averaged over a 20-min period.  For the measurement of proteinuria, urine was 
collected for analysis using metabolic cages (Nalgene, Rochester, NY).  Total 
microalbumin and creatinine in the urine were determined by using ELISA kit 
(Exocell, Philadelphia, PA) and then the ratio of urinary albumin to creatinine was 
calculated as an index of proteinuria. 
Immunohistochemistry/Immunofluorescence 
Tissues were paraffin fixed and sectioned using standard 5 µM sections 
and mounted onto glass slides. To begin 
immunohistochemistry/immunofluorescence protocol, all slides were 
deparaffinized using a standard deparaffinizing protocol. Tissue sections were 
marked with wax pens and blocked for 30 minutes using a standard blocking 
reagent (Vector Labs, Burlingame, CA). Anti-human and anti-mouse primary 
antibodies were diluted 1:50-1:200 in blocking buffer and incubated in a 
humidified chamber overnight at 4°C. Slides were washed in phosphate buffered 
saline and subsequently incubated in secondary antibody raised against the 
primary antibody host at room temperature for 30 minutes (Vector Labs, 
Burlingame, CA). Slides were then incubated with an alkaline phosphatase 
substrate mixture for 45 minutes (Vector Labs, Burlingame, CA). Slides were 
developed using a dual alkaline phosphatase/fluorescent development solution 
(Vector Labs, Burlingame, CA). Slides were counterstained with hematoxylin and 
differentiation solution. All slides were mounted with a 4’, 6-diamidino-2-
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phenylindole (DAPI) antifade solution (Life Technologies, Grand Island, NY) and 
sealed. Images were taken with Olympus BX-60 microscope and camera. All 
fluorescent images were digitally aperture standardized 
Western Blotting 
Presence of CRP was analyzed by previously described western blotting 
procedures. To confirm expression within the tissue, all tissues were cut to ~50 
mg and homogenized in RIPA buffer with protease inhibitors (Santa Cruz 
Biotechnologies, Dallas, TX). Protein concentrations of tissue lysate were 
measured by BCA assay (Pierce). To analyze by western blotting, 20-40 ug of 
protein were loaded onto 4-20% stacked SDS-PAGE gels (Bio-rad, Hercules, 
CA) and transferred onto Polyvinylidene Fluoride (PVDF-FL) membranes 
(Millipore, Billerica, MA). Membranes were probed with anti-human or –mouse 
primary antibodies raised against CRP in 1:500 dilutions (Abcam, Abbiotec; 
Cambridge, UK, San Diego, CA, respectively). A 43-kDa actin (Sigma, St. Louis, 
MO) housekeeping antibody was used as a loading control. Fluorescent 
conjugated secondary antibodies were used for visualization of the membrane on 
LICOR imaging systems (LICOR, Lincoln, NE).  
Placental Villus Explant Culture 
Placental tissue from NT patients was obtained within 20 minutes of 
placental delivery. Placentas were transported on ice and prepared for 
processing. Placental tissue was isolated from the periphery of the placenta 
subcapsularly. 50 mg segments of placenta were perfused in DPBS, and then 
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rinsed 2x in phenol red free Dulbecco’s Modified Eagle Medium (DMEM) (10% 
FBS; 1% Pen-Strep). Placenta segments were manually separated using 
scissors and forceps and incubated overnight at 37°C/5% CO2 in phenol red free 
DMEM in 12-well plates. Villi were then treated with CRP or various antagonists 
or siRNA treatment via nanoparticle encapsulated siRNA constructs prepared as 
previously described in the “animals” method section. Placental villus explants 
and tissue culture media was then harvested after a 48 hour period and stored at 
-80°C. 
Enzyme-linked Immunosorbent Assay (ELISA) 
Determination of CRP and sFlt-1 levels were quantified by commercially 
available ELISA kits. Human sera and/or plasma were diluted 100-fold (human 
CRP,Life Technologies, Grand Island, NY; murine CRP, Exocell, Philadelphia, 
PA) or 4-fold (NKB; RayBiotech, Norcross, GA). sFlt-1 (R&D Tocris, Bristol, UK)  
was detected in either murine sera or placental villus explant culture media. For 
microalbumin/creatinine quantifications, murine urine was diluted 13-fold 
(albumin) or 20-fold (creatinine) for quantification by Exocell albuwell and 
creatinine companion kits. 
Quantitative Real Time-PCR 
RNA was obtained from human and mouse placentas via RNeasy Mini Kit 
(Qiagen, Venlo, Netherlands). RNA was transcribed into single-strand cDNA with 
use of a reverse transcription kit (Qiagen, Venlo, Netherlands). cDNA was 
analyzed by qRT-PCR using SYBR green (Qiagen, Venlo, Netherlands) via 
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specific primers to assess mRNA relative copy counts in the sample (Table 2). 
Results were calculated using 2-ΔCt method using actin as housekeeping gene 
for ratio comparison.62 
 
Table 2. qRT-PCR Primers 
Primer Sequence (5'→3') 
hCRP For AGG CCC TTG TAT CAC TGG CAG CA 
hCRP Rev CCA TAG CCT GGG GTG GCC CTT A 
mPCYT1B 
For GTC ACG CAA GGG CAC TTA TG 
mPCYT1B 
Rev GAG TAA GGT CAT CAC TGC AAA CT 
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Histologic Analysis 
The kidneys and placentas of mice were formalin fixed and processed 
according to standard protocols. The tissues were sectioned in 5 µM serial 
sections and were stained via hematoxylin and eosin by standard pathology 
protocol. Glomeruli and placenta were examined by single-blinded study. 
Number and scoring of glomeruli was assessed by counting and averaging the 
number and score of glomeruli per 10 random high powered fields (40x 
magnification). Scoring was based on glomerular health: (1) corresponded to 
decreased bowman capsule space, intraglomerular loop dilation, and tubular 
dilation; (5) corresponded to adequate bowman capsule space, no loop dilation, 
and normal tubule diameter. Further description of glomerular scoring is provided 
in Zhang, et al., 2013.63, 64 Placenta calcification quantification was assessed by 
quantification of calcifications under 10 high powered fields. Both sets of 
quantification were performed via blinded analysis using Image Pro Plus 
software. 
Statistical Analysis 
All data were statistically analyzed with use of Graph Prism Pro v5.0, and 
the data were subjected to student’s t-test (paired and unpaired), two-way 
ANOVA, and Tukey’s test, where appropriate. Accepted variance was 
standardized to p < 0.05. Data were graphed on Graph Prism Pro v5.0 or 
SigmaPlot, where appropriate. 
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Results 
CRP is elevated in PE human patient samples 
Aberrant innate immune factors are thought to underlie the pathogenesis 
of PE. Previous literature has demonstrated that aberrant inflammatory 
upregulation is integral in the pathogenesis of PE. To assess the inflammatory 
status of PE patients, we began by examining levels of CRP within our PE 
human patient population. Given that CRP is thought to be elevated prior to the 
onset of PE symptoms, we measured CRP levels to determine elevated levels up 
to delivery of the fetus. Using ELISA assays, we assayed CRP levels in patient 
sera from term delivery. We also utilized a normotensive nulligravid patient 
cohort as control. We observed a 3-fold increase in CRP levels in PE patients 
versus NT patients with term pregnancies. Additionally, CRP levels were found to 
be below the threshold of assay detectability in nulligravid patients (Fig. 1-2).  
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Figure 1-2. CRP is elevated in PE patient sera and is produced in PE patient 
trophoblastic tissue 
(Left) Circulating CRP in sera was detectable on average 60 μg/mL in PE 
patients sera (n=15) and approximately 3-fold less in normotensive (NT) (n=15) 
patients. In a nulligravid cohort (n=21), levels were below the threshold of the 
assay. (Right) CRP mRNA transcripts were detected in patient placental 
samples. In samples isolated from PE patients, transcripts were elevated 4-fold 
than those samples isolated from NT patients. ** = p < 0.05 from NT; * = p < 0.05 
from NG 
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While levels of CRP were detected in sera, we wanted to investigate other 
sources of CRP production. While hepatic tissue is the primary organ of CRP 
production and release, syncytiotrophoblastic tissue was analyzed using qRT-
PCR techniques for the presence of mRNA for the CRP gene. Novelly, our group 
demonstrated that PE placental tissue does transcribe the CRP gene and could 
be a pathologic source of CRP production. Next, we performed western blot 
analysis and found that CRP protein levels were also  increased  in  PE 
compared to the NT placentas (Fig. 1-3).  Moreover, immunohistochemistry and 
immunofluorescence dual-staining demonstrated that CRP was localized in the 
villus syncytiotrophoblast cells, around the villus border (Fig. 1-3).  Thus, we 
have shown that 1) syncytiotrophoblast cells in the placenta express CRP and 
contribute to increased circulating CRP under normal pregnancy state; 2) 
elevated placental CRP is an additional source responsible for substantial 
increased CRP under PE conditions. 
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Figure 1-3. CRP is elevated in PE patient placental tissue as confirmed by 
immunoblotting and immunohistochemistry/immunofluorescence. 
(Top panels) CRP deposition within PE placentas is significantly elevated versus 
deposition within NT placentas as confirmed by immunoblotting. (Bottom panel) 
CRP is elevated within the external villus syncytiotrophoblast cells in PE 
placentas as confirmed by immunohistochemistry and immunofluorescence. CRP 
is poorly detected in placental syncytiotrophoblastic tissue isolated from NT 
placentas on immunohistochemistry and immunofluorescence. 40x magnification; 
Scale bar = 100 μm  
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CRP induces pathophysiology of PE in pregnant mice but not nonpregnant mice  
To examine the pathogenic role of CRP in PE, we infused CRP into 
pregnant C57BL/6 mice on E13 and E14 of their gestation period to achieve a 
similar concentration as PE patients. Our data indicate that a pathological 
concentration of CRP seen in PE patients at term (75 μg/mL; based on the upper 
standard deviation detectable in our circulating CRP ELISA; Fig. 1-2) was 
sufficient to cause an elevation in mean systolic pressure in CRP-infused mice 
(157.08 mmHg vs. 118.99 mmHg control) (Fig. 1-4). To verify the level of CRP 
injected into mice, sera was sampled at the endpoint of the experiment on E18 
and measured by ELISA. We observed a mean level of 11.6 μg/mL of circulating 
CRP in our mice. The level of CRP on E18 is consistent with extrapolated 
predictions of two injections of 75 μg/mL on E13/14. Proteinuria was also 
significantly elevated in CRP-infused mice (Fig. 1-4). Similar to PE patients, both 
hypertension and proteinuria were significantly dropped to the basal levels 
postpartum (Fig. 1-4).   
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 Figure 1-4. CRP injections into pregnant C57BL/6 mice result in key 
features of PE—hypertension and proteinuria—which resolve by post-
partum day 10. 
(Left) 75 ug/mL IV injections on E13/E14 induced mean systolic pressure 
elevation by E14.5 and dropped postpartum day 5-10. * = p < 0.05; ** = p <0.05 
from CRP E17.5 (n=5-8). (Right) Microalbuminuria/creatinine ratio assayed by 
ELISA was significantly increased in the mice injected with CRP but diminished 
by postpartum D10. * = p < 0.05; ** = p < 0.05 vs. CRP peri-partum (n=5-8).  
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 Additionally, histological studies demonstrated the typical glomerular 
damage featured with decreased capillary lumen space and narrowing Bowman’s 
capsule space (Fig. 1-5).  Histologic glomerular scoring, indicating an overall 
decrease in the health of the glomerulus in the outer renal cortical region (Fig. 1-
5). Furthermore, histological studies showed that increased placental damage 
characterized with increased placental calcification in the CRP-infused pregnant 
mice (Fig. 1-5).  Altogether, we provide the first evidence that CRP infusion 
directly induces pathophysiology of PE in pregnant mice as seen in PE patients. 
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 Figure 1-5. CRP induces renal and placental damage in a pregnant mouse 
model. 
(Top Left) Oil-immersion microscopy showed CRP injection resulted in impaired 
glomerular histological condition. (100x magnification; scale bar = 50 μm) (Top 
Right) Blinded quantification of glomerular sections revealed a decrease in 
glomerular score of CRP injected murine renal histological sections (n=10 fields 
per kidney; 7 animals). * = p < 0.05 (Bottom Left) Analysis of placental sections 
at 20x microscopy reveals significant placental damage as reflected by an 
increase in placental calcification and scarring in placentas of CRP injected mice  
(Arrows: indicate placental calcification; scale bar = 200 μm). (Bottom Right) 
Confirmation by random high-powered field quantifications of placental sections 
(n=10 fields per placenta; 7 animals). * = p < 0.05.   
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Next, to determine whether CRP-induced PE pathophysiology is 
dependent on pregnancy, we infused similar concentrations of CRP into 
nonpregnant mice.  The key features of PE including hypertension and 
proteinuria were not observed in CRP-infused nonpregnant mice (Fig 1-6). sFlt-1, 
a pathogenic factor, is predominantly produced in the placentas and known to be 
induced by inflammatory factors.2, 6, 10, 34, 49, 64-69  Thus, CRP may be a previously 
unrecognized factor contributing to increased sFlt-1 production in the placentas 
and subsequently leading to PE.  Supporting this possibility, we found that sFlt-1 
levels in the sera were significantly increased in the pregnant mice with infusion 
of CRP compared to the control pregnant mice (Fig.1-6).  In contrast, sFlt-1 
levels were extremely low and no difference observed in the nonpregnant mice 
with or without CRP infusion (data not shown).  Thus, we demonstrated that CRP 
is a novel pathogenic factor contributing to pathophysiology of PE including 
hypertension, proteinuria, kidney and placental damage and increased sFlt-1 
secretion. 
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 Figure 1-6. CRP injections in nonpregnant animals result in no increased 
hypertension and proteinuria. In pregnant animals it also induces sFlt-1 
expression and release. 
(Left) Nonpregnant mice injected with equivalent CRP concentrations (n=5) 
exhibited no elevation in mean systolic pressure versus nonpregnant mice 
injected with IV saline (n=10). (Middle) Microalbumin/creatinine ratio was not 
significantly altered in CRP injected nonpregnant mice relative to saline injected 
controls. (n=5-10)  (Right) sFlt-1 level in the circulation was induced by CRP 
injection in pregnant mice. * = p < 0.05.  
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 Antagonism of NK3R or specific knockdown of NK3R attenuates CRP-induced 
pathophysiology of PE in pregnant mice 
Because CRP binds with phosphocholine and phosphocholinated NKB 
(PC-NKB) preferentially activates NK3R, it is possible that CRP-induced 
pathophysiology is dependent on NK3R activation. To test this intriguing 
possibility, we treated CRP-infused mice with or without NK3R specific inhibitor, 
SB222200.  We found that SB222200 treatment significantly reduced mean 
systolic pressure and proteinuria in CRP-infused pregnant mice (Fig 1-7). 
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 Figure 1-7. CRP-induced hypertension and proteinuria is attenuated by 
competitive NK3R inhibitor or in vivo siRNA knockdown of NK3R. 
(Left) Co-injection of SB222200 prevented CRP induced   mean systolic pressure 
of pregnant mice when administered on E13/E14. Administration of nanoparticle-
encapsulated siRNA with CRP on E13/14 also reduced the CRP induced mean 
systolic pressure of the pregnant mice. * = p < 0.05 CRP + scrambled vs. CRP + 
siNK3R and CRP + SB222200; (n=5-8). (Right) Cotreatment with either 
SB222200 or NK3R siRNA reduced microalbuminuria/creatinine ratio. * = p < 
0.05  
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 There was a marked reduction in glomerular damage as indicated by an 
overall improvement tubular diameter, Bowman’s capsule diameter and 
glomerular scoring (Fig. 1-8). We also observed a decrease in placental 
calcifications of CRP-infused pregnant mice with SB222200 treatment (Fig. 1-8).  
To further validate our pharmacological studies, we performed an in vivo 
knockdown of the NK3R via encapsulation of siRNA specific for the NK3R by a 
nanoparticle delivery system (Altogen). First, we demonstrated that siRNA 
specific for NK3R significantly reduced more than half of NK3R protein levels in 
the placentas compared to the scrambled siRNA in the CRP-infused pregnant 
mice (Fig. 1-8). In contrast, the efficiency of knockdown of NK3R in the kidneys 
was less evident compared to the placental tissues.  Thus, we concluded from 
these results that siRNA specifically for NK3R successfully reduced NK3R in the 
placentas but not kidneys in the CRP-infused pregnant mice.  Next, we found 
that knockdown of NK3R more than half by specific siRNA was sufficient to 
attenuate mean systolic pressure and proteinuria in CRP-infused pregnant mice 
compared to the pregnant mice with nanoencapsulated scrambled RNA (Fig. 1-
8). Furthermore, CRP-induced placental calcifications, kidney damage and 
increased circulating sFlt-1 levels were significantly attenuated by specific NK3R 
siRNA knockdown in pregnant mice (Fig. 1-8). Thus, both pharmacological 
studies using specific NK3R antagonist and quasi-genetic studies using siRNA to 
specific knockdown of NK3R provide strong in vivo evidence that CRP-induced 
PE pathophysiology is signaling via NK3R. 
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Figure 1-8. Antagonism of NK3R or siRNA knockdown for NK3R attenuates 
CRP-mediated renal and placental damage. 
(Top panels) Glomerular damage was significantly attenuated by 
coadministration of SB222200 or NK3R siRNA as shown by H&E stained renal 
sections. (100x magnification; scale bar  =  50 μm) (Middle panels) Placental 
damage was attenuated by cotreatment of SB222200 or NK3R siRNA, as 
indicated by reduction of placental calcifications and scarring shown on H&E 
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placental sections. (20x magnification; scale bar = 200 μm) (Bottom left panel) 
Histologic scoring of glomerular damage based on double-blind scoring criteria 
(n=10 fields per kidney; 7 animals). (Bottom right panel) Quantification of 
placental calcifications based on blinded image analysis (Arrows: indicate 
placental calcification; n=10 fields per placenta; 7 animals). * = p < 0.05  
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Finally, treatment with SB222200 decreased CRP-induced sFlt-1 levels in the 
pregnant mice (Fig. 1-9). 
 
Figure 1-9. Antagonism with NK3R pharmacologic antagonist or siRNA 
knockdown of NK3R attenuates sera sFlt-1 levels  
sFlt-1 production is significantly attenuated in pregnant mice with co-
administration of SB222200 or siRNA for NK3R. * = p < 0.05  
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Knockdown of phosphocholine transferase ameliorates CRP-induced PE 
features in pregnant mice 
Because NKB is modified by placental phosphocholine transferase (PCT) 
(i.e. PCYT1b) and PC-NKB preferentially activates NK3R, it is possible that CRP-
mediated activation of NK3R and subsequent disease development are 
dependent on the placental PCT.  To overcome the difficulty of lack of a potent 
and specific inhibitor for PCT, we performed quasi-genetic studies using 
nanoparticle encapsulated siRNA specifically to knockdown the synthesis of this 
important enzyme in CRP-infused pregnant mice.  First, we confirmed that siRNA 
specific for PCT significantly reduced mRNA of this enzyme in the placentas of 
CRP-infused mice compared to the scrambled siRNA (Fig. 1-10).  Additionally, 
knockdown of PCYT1b by specific siRNA for PCT significantly attenuated mean 
systolic pressure and proteinuria in the CRP-infused pregnant mice versus the 
CRP-infused pregnant mice injected with scrambled siRNA (Fig. 1-10).  
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 Figure 1-10. In vivo siRNA knockdown of phosphocholine transferase 
attenuates mean systolic pressure and proteinuria. 
(Left) Confirmation of knockdown is shown by qRT-PCR on placental lysates 
(n=5). Administration of nanoparticle-encapsulated siRNA for PCYT1b with CRP 
on E13/14 reduced the mean systolic pressure of the pregnant mice. * = p < 0.05 
(Right) Cotreatment of PCYT1b siRNA reduced microalbuminuria/creatinine ratio. 
* = p < 0.05  
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Furthermore, CRP-induced placental calcifications, kidney damage and 
increased circulating sFlt-1 levels were significantly attenuated by specific PCT 
siRNA knockdown in pregnant mice (Fig. 1-11). Thus, quasi-genetic studies 
using siRNA to specifically knockdown PCT revealed that placental PCT, which 
is a key enzyme responsible for NKB phosphocholination, is essential for CRP-
induced PE pathophysiology. 
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 Figure 1-11. In vivo siRNA knockdown of phosphocholine transferase 
attenuates renal and placental damage, as well as sFlt-1 production and 
release. 
(Top panels) Glomerular damage was significantly attenuated by 
coadministration of PCYT1b siRNA as shown by H&E stained renal sections. 
(100x magnification; scale bar = 50 μm) (Middle panels) Placental damage was 
attenuated by cotreatment with PCYT1b siRNA, as indicated by reduction of 
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placental calcifications and scarring shown on H&E placental sections. (20x 
magnification; scale bar = 200 μm) (Bottom left panel) Histologic scoring of 
glomerular damage based on double-blinded scoring criteria (n=10 fields per 
kidney; 7 animals). * = p < 0.05 (Bottom middle panel) Quantification of placental 
calcifications based on blinded image analysis (n=10 fields per placenta; 7 
animals). * = p < 0.05. (Bottom right panel) CRP induced sFlt-1 production was 
significantly attenuated in pregnant mice with coadministration of SB222200 or 
siRNA for PCYT1b. * = p < 0.05 
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Elevated CRP and NKB are co-localized in syncytiotrophoblast cells of placentas 
of PE patients 
To extend our mouse findings to human, we performed 
coimmunofluorescence staining to determine the localization of CRP and NKB in 
the term placentas from NT pregnant women and PE patients.   Specifically, we 
found that CRP and NKB were observed in the syncytiotrophoblast cells of the 
maternal villi and substantially increased in the placentas of PE compared to NT 
pregnant women (Fig. 5A). Additionally, co-localization of CRP and NKB was 
visualized along the cellular membrane of the villus syncytiotrophoblast cells (Fig. 
1-12). It is interesting to note that the CRP and NKB were extranuclear and 
mainly outside of the cytoplasm of the trophoblast cells.  Thus, these translational 
human studies demonstrated that CRP and NKB are elevated and colocalized in 
the syncytiotrophoblast cells in human placentas from PE patients.  
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Figure 1-12. CRP and NKB colocalize within placental syncytiotrophoblast 
cells in PE patient placentas. 
Coimmunofluorescence revealed increased CRP and NKB in syncytiotrophoblast 
cells in terminal villi. On the merged image, membrane colocalization was 
visualized along the syncytiotrophoblast cells. Some autofluorescence can be 
seen intravascularly due to the presence of autofluorescent RBCs. (40x 
magnification; scale bar = 100 μm). 
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CRP signaling via NK3R directly induces sFlt-1 secretion from cultured human 
placental villus explants in a PCT-dependent manner  
Although we showed that CRP-induced hallmark features including 
hypertension, proteinuria and increased circulating sFlt-1 levels in an intact 
animal by activating NK3R and in a PCT-dependent manner, the pathological 
role of CRP in humans remains unidentified.  To test the significance of CRP in 
PE in humans, we took advantage of primary cultured human villous explants to 
determine if CRP signaling via NK3R contributes to PE by directly inducing sFlt-1 
secretion in a PCT-dependent manner.  Similar to mouse finding, we found that 
CRP treatment directly induced sFlt-1 secretion from cultured human villous 
explants from NT pregnant women at term (Fig. 1-13).  Moreover, SB222200, a 
specific inhibitor of NK3R, and siRNA specific for NK3R significantly reduced 
CRP-induced sFlt-1 secretion from cultured human villous explants (Fig. 1-13). 
Finally, siRNA specific for PCT also significantly reduced CRP-induced sFlt-1 
secretion from cultured human villous explants (Fig. 1-13). Taken together, these 
results translate our mouse finding to human pregnancy by showing that CRP 
signaling via NK3R contributes to sFlt-1 secretion in a PCT-dependent manner 
from cultured human villous explants. 
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 Figure 1-13. sFlt-1 production is significantly attenuated in the presence of 
antagonist of NK3R and knockdowns of NK3R and phosphocholine 
transferase in cultured placental villus explants  
Placental villus explants isolated from normal patients and treated with or without 
CRP in the presence or absence of series of drugs or siRNA. CRP directly 
induced secretion of sFlt-1 from cultured human villus explants, but this increase 
was attenuated by treatment with SB222200 or siRNA for NK3R or PCYT1b. * = 
p < 0.05 difference from control; # = p < 0.05 difference from CRP + scrambled.  
(n = 4 wells placental villous explant culture)   
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Discussion 
CRP is increased in the circulation at early stage prior to PE symptoms 
and its elevation is correlated to the disease severity.  However, nothing is known 
about its role in PE, the specific cell types responsible for its increased 
production and the molecular basis for its function. Here we have provided 
human evidence showing that CRP transcripts are present in syncytiotrophoblast 
cells of normal placentas and further increased in the PE placentas, indicating 
that syncytiotrophoblast cells in the placenta are a previously unrecognized 
additional source for increased circulating CRP seen in PE patients.  Extending 
human studies we have further demonstrated the pathogenic nature of CRP in 
PE by showing that injection of CRP alone is sufficient to regenerate the key 
features of PE including hypertension, proteinuria, kidney damage and impaired 
placentas in pregnant mice. Mechanistically, we revealed CRP signaling via 
NK3R contributes to sFlt-1 secretion and disease development in PCT-
dependent manner in intact animals and in cultured human villous explants.   
Overall, we have provided both human and mouse evidence that increased CRP 
contributes to PE pathophysiology by cross-talking with PCT and NK3R.  Thus, 
our findings have identified the detrimental role of CRP, new sources for its 
production and a novel signaling cascade for its pathogenic effects in PE. These 
findings suggest novel therapeutic opportunities 
CRP is predominantly produced by hepatocytes under nonpregnant 
states. Prior to our studies it was unclear what specific cell type was responsible 
for increased circulating CRP in PE patients.  Here we demonstrated for the first 
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time that placentas contain transcripts for CRP and CRP transcript levels are 
significantly increased in the placentas of PE patients compared to NT pregnant 
individuals.  However, CRP levels are virtually undetectable in nulligravid women.  
Using immunohistological studies, we further found that CRP is predominantly 
expressed in syncytiotrophoblast cells of human placentas.  Thus, we provide 
human evidence that placental syncytiotrophoblast cell is a previously 
unrecognized cell type expressing CRP and it is additional source contributing to 
circulating CRP in PE patients.  Understanding how CRP gene expression is 
regulated under physiological and pathological pregnancy will be important 
questions for us to further address. 
CRP is an innate immune factor and works with complement components 
to kill the bacteria and virus or remove damaged tissues. Because of its early rise 
in the inflammatory process, CRP is often considered as an important early 
predictor for the immune response.  Although the transient elevation of CRP in 
response to the presence of pathogens is beneficial, the prolonged and 
persistent elevation of CRP is likely harmful resulting in damage to host 
tissues.42, 43, 45, 46, 70, 71 Some studies have suggested that obesity and increasing 
BMI, correlated with late-onset PE, are key factors in increasing CRP and those 
cytokines instrumental in its production and release.72 However, multiple human 
studies have shown that circulating CRP is elevated at the early stage prior to 
clinical symptoms in PE patients and its level is correlated to the severity of the 
disease.44, 47  Moreover, several studies indicate that the elevation of circulating 
CRP is correlated to multiple pathogenic factors including TNF-α, IL-6, excess 
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complement production and soluble VEGF, implicating its role in endothelial 
dysfunction, uterine arterial constriction, macrophage activation, and arterial 
plaque formation.9  However, the pathogenic role of elevated circulating CRP in 
PE has not been previously examined in vivo.  Here we demonstrated for the first 
time that injection of CRP to achieve similar concentrations to those seen in PE 
patients induced hallmark features of PE including hypertension, proteinuria, 
kidney damage and placental impairment in pregnant mice.  Because PE is a 
pregnancy related disease, the placenta has been long considered to play an 
important role in the disease development. To examine the role of placentas in 
CRP-induced hypertension and proteinuria, we injected similar amount of CRP 
into nonpregnant as pregnant mice.  In contrast to pregnant mice, CRP failed to 
induce PE features in nonpregnant mice. These findings are consistent with 
reports of LaMarca and colleagues showing that TNF-α, IL-6, and IL-17 can only 
induce high blood pressure in pregnant rats, not in nonpregnant rats.29, 30, 33 We 
further discovered that CRP induces sFlt-1 production in pregnant mice but not 
nonpregnant mice, suggesting the placenta as the source of increased sFlt-1.  
Extending our mouse studies, we have demonstrated that CRP directly induces 
sFlt-1 secretion from cultured human villous explants. Elevated sFlt-1 contributes 
to pathophysiology of PE including abnormal placentation, hypertension and 
kidney injury.3 Thus, a possible explanation for CRP only inducing PE features in 
pregnant mice but not nonpregnant mice is that CRP only induces secretion of 
placental derived toxic factor, sFlt-1, during pregnancy.  Taken together, our 
studies revealed that elevated CRP is a potent immune mediator responsible for 
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increased sFlt-1 secretion and impaired placentas.  Without interference, CRP-
sFlt-1-placental damage functions as malicious cycle leading to progression of 
the disease and symptom development (Fig. 1-14). 
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 Figure 14. Working Model: CRP and PC-NKB communicate with the NK3R 
to elicit features of PE. 
CRP is expressed in the placentas and elevated CRP in the syncytiotrophoblast 
cell is additional source underlying increased circulating CRP in PE patients.  
Locally-synthesized CRP cross-talks with post-translationally modified 
phosphocholinated NKB (PC-NKB) by placental-specific enzyme, PCT. 
Subsequently, CRP and PC-NKB work together preferentially activates NK3R 
leading to increased sFlt-1 production and release. Our findings reveal novel 
mechanisms for pathogenesis of PE and identify innovative therapeutic 
possibility for prevention and treatments. 
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NKB is mainly secreted from brain and placentas. Early human studies 
found that circulating NKB is significantly elevated in PE patients.57, 58, 61 More 
recent studies showed that endogenous NKB is modified by phosphocholine 
transferase (PCT). The phosphocholinated NKB (PC-NKB) preferentially 
activates NK3R, a Gq coupled receptor.  As such, elevated NKB activating NK3R 
induces calcium influx and subsequent vascular hypertension and kidney 
damage.  During infection, CRP binds with phosphocholine on the membrane of 
bacteria and virus and works with complement systems and inflammatory cells 
together to eventually kill foreign invaders. Here we have provided multiple lines 
of evidence supporting a novel but compelling molecular basis that under PE 
condition in the absence of infection, increased CRP signaling via NK3R 
contributes to PE pathophysiology in a PCT-dependent manner. First, we have 
provided in vivo animal evidence that CRP-induced PE pathophysiology is 
significantly reduced by blocking NK3R signaling by its specific antagonist or by 
lowering its protein levels by its specific siRNA.  Subsequently, using quasi-
genetic studies to specific knockdown PCT, CRP-induced PE features in the 
pregnant mice are significantly ameliorated.  Thus, both pharmacological and 
quasi-genetic studies provide strong in vivo functional evidence that PCT 
mediated NKB phosphocholination, and NK3R signaling underlies CRP-induced 
pathogenic effects in pregnant mice.  
We have further validated our mouse finding and provided human 
evidence showing that NKB and CRP are co-localized in membrane of 
syncytiotrophoblast cells of villous human placentas and their levels were 
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significantly increased in the placentas of PE patients compared to the NT.  
Similar to our mouse finding, we have demonstrated that CRP signaling via 
NK3R directly induces sFlt-1 secretion from cultured human villous explants in a 
PCT-dependent manner. PCT is only known to be expressed in two organs 
including placentas and testis.  So far, two endogenous molecules are identified 
to be modified by PCT, i.e., NKB and corticotropin releasing factor (CRF).60  
PCT-mediated PTM of these two molecules is considered leading to PC-NKB 
preferentially activating NK3R and preventing PC-CRF degradation in circulation, 
respectively.  Because placenta serves as the only source of PCT necessary for 
posttranslational phosphocholination of NKB, PE features were not observed in 
nonpregnant CRP-injected mice.  Thus, our findings support a novel working 
model: increased CRP functionally coupled with PCT, a key enzyme carrying 
posttranslational modification of NKB only occurring in the placentas, 
preferentially activates NK3R and subsequently promote disease development 
(Fig. 1-14). Interfering with these pathogenic molecules including placental 
specific PCT and NK3R are promising therapeutic possibilities (Fig.1-14). 
Although our results clearly show that PCT and NK3R signaling are functionally 
required for pathogenic role of CRP in PE, we have been unable to demonstrate 
how PCT-mediated PC-NKBs cross-talk with CRP.  In view of important role of 
PCT and NK3R in CRP-induced pathophysiology of PE, one of the most 
reasonable possibilities is that CRP and PC-NKB directly interact and then this 
complex preferentially activates NK3B and leads to PE features.  Although our 
human studies have showed that CRP and NKB are co-localized on the 
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membrane of syncytiotrophoblast cells of human placentas, our 
coimmunoprecipitation pull down assay has been unable to show a direct 
interaction of these two molecules.  Our lack of success may reflect a weak 
interaction that does not persist through such experiments or low abundance of 
PC-NKB that does not allow us to pull down the complex.  Nevertheless, lacking 
direct evidence for the interaction of CRP with PC-NKB does not prevent us to 
conclude that CRP is pathogenic for PE functioning through NK3R signaling in a 
PCT-dependent manner.  Thus, the important and clear evidence of CRP 
functionally dependent on NK3R and PCT  leads to several exciting new 
directions including determining the molecular mechanisms by which CRP 
pathogenesis requires PCT and activates NK3R signaling and developing a 
specific and potent PCT and NK3R inhibitors to treat PE.   
In conclusion, our findings are innovative since little was known about the 
role of CRP and placental PCT in PE until data suggested that placental PCT 
and NK3R are key factors responsible for CRP-induced pathophysiology of PE.  
Moreover, our discovery that placentas contain CRP transcripts and 
syncytiotrophoblast cells contribute to increase in circulating CRP in PE patients 
are also novel.  Finally, our findings are clinically significant since we have 
determined  that CRP is not only an early biomarker, but it has a pathogenic role 
in PE Thus, our current studies have added significant new insight to the 
pathogenesis of PE, have revealed early pre-symptomatic pathogenic biomarker 
and thereby have opened up novel therapeutic possibilities for the disease 
prevention and treatment.  
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 NOVELTY AND SIGNIFICANCE 
What Is New? 
• An acute inflammatory mediator, CRP, is elevated in the circulation and 
placentas of women with PE. Thus, placenta may be an additional source 
contributing to elevated CRP in PE 
• Injection of recombinant murine CRP into pregnant mice results in 
increased sFlt-1 production, hypertension and proteinuria via cross-talk with NKB 
and subsequent activation of NK3R.  
• A critical role for placenta-specific phosphocholine transferase (PCTY1b) 
in the modification of NKB was identified in CRP-induced pathophysiology of PE. 
• CRP-NKB cross-talks with neurokinin 3 receptor (NK3R), increasing sFlt-1 
production in cultured human placenta villous explants in an PCTY1b dependent 
manner 
What is relevant? 
Our data reveal a previously unrecognized pathogenic role of CRP signaling via 
NK3B in the pathogenesis of PE dependent on placental specific enzyme, 
phosphocholine transferase, highlighting potential therapeutic possibilities. 
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Summary 
We report that CRP, previously thought to be a nonspecific inflammatory 
mediator, is elevated in circulation of normotensive pregnant women compared 
to nulligravid women and further elevated in women with PE.  Additional 
experiments determined that CRP is produced by the syncytiotrophoblasts of the 
placenta.  We demonstrated the pathogenic role of CRP by infusion of 
recombinant CRP into pregnant mice to show features of PE, including 
hypertension and proteinuria. Furthermore, by antagonism or knockdown of the 
NK3R using pharmacologic or siRNA methodology, we found that this receptor is 
essential for the CRP-induced features of PE including hypertension, proteinuria, 
placental and kidney pathology. Additionally, we found that the placenta-specific 
enzyme, phosphocholine transferase (PCTY1b), was required for the CRP-
induced pathophysiology in pregnant mice. Finally, we validated our mouse 
studies in human and showed that CRP induced sFlt-1 secretion by isolated 
human placental villus explants via NK3R activation in a PCTY1b-dependent 
manner. Altogether, our human and mouse studies reveal CRP cross talks with 
NKB signaling contributes to pathophysiology of PE in a PCTY1b-depenent 
manner, and thereby highlight potential therapeutic possibilities.  
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CHAPTER II: 
Role of Transgenerational Epigenetic Modifications of the AT1R on the 
Pathogenesis of Adult-Onset Hypertension   
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Introduction 
Transgenerational Features of Disease 
 A developing field of research characterizes the role in in utero imprinting 
and transmitting disease to future generations called fetal programming. Fetal 
programming is encompassed into a broader field termed epigenetics. It was 
previously thought that only genetic factors could affect the development of a 
fetus. However, recent evidence points to the complex relationship between 
genetic and environmental factors which can affect fetal development and 
organogenesis.22, 73 Epigenetics concerns all changes that can affect genetic 
expression above the genome. Alterations in expression occur from a variety of 
mechanisms—histone modifications, RNA interference, or DNA promoter 
methylation.22, 74, 75 These modifications affect the overall accessibility of the DNA 
sequence and facilitate or inhibit replication and transcription. Of these 
modifications, literature indicates that DNA promoter methylation is important for 
transgenerational passage of epigenetic imprinting to subsequent generations.18, 
76, 77 
 DNA promoter methylation involves modifications at the DNA promoter 
level to affect transcription of the DNA. Specifically, methyl group attachment to 
the C5 position of cytosine residues serves to modify individual DNA bases. The 
methyl group attachment primarily occurs within regulatory sequences call CpG 
islands, regions rich in cytosine and guanine (CG) base pairs.21, 78 
Hypermethylation of these sequences is important for transcriptional repression 
and inactivation of gene expression at certain developmental time points. 
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Likewise, hypomethylation can be an equally important modification to affect 
genetic expression. However, hypomethylation and its role in transcriptional 
regulation is poorly investigated. It is thought that global decreases in methylation 
can be precipitated by decreases in DNA methylation transferase 1 (DNMT1).79 It 
is known that DNA hypomethylation plays essential roles in brain development, 
cancer, and cardiovascular diseases.80, 81 However, the specific mechanisms 
underlying hypomethylations in this disease processes remain a mystery.  
 While global hypomethylation is presumed to precipitate disease 
processes, the mechanism underlying this process is undefined. One mechanism 
thought to determine methylation status on promoters is in utero stress.  
Preeclampsia is a type of intrauterine stress thought to predispose the fetus to 
future problems. To note, women who have one pregnancy affected by PE are 
more likely to have late life cardiovascular or renal disease.21, 82-84 Likewise, 
progeny exposed in utero to PE have a higher incidence of cardiovascular 
disease, metabolic disease, and inflammatory conditions.21, 22, 82-98 These 
features are witnessed in the absence of known genetic mutations, leading to the 
presumption that other mechanisms may be involved. Based on previous 
literature, hypomethylation and inactivation of DNMT1 could be potential factors 
in late-life hypertension. 
Disturbance of Renin-Angiotensin-Aldosterone (RAAS) Signaling as a 
Pathogenic Factor in PE and Hypertension 
 One of the hallmarks of hypertensive disorders is disturbances in 
hypertensive signaling pathways and failures of the systems to counteract them. 
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One of the drivers of hypertension and PE is disruptions of the RAAS. The 
classical RAAS pathway involves signaling of pressors to counteract a 
depression in blood pressure sensed by the juxtaglomerular apparatus (JGA) in 
the kidney. JGA cells synthesize renin which catalyzes the conversion of 
angiotensinogen to angiotensin I (Ang I). Ang I is subsequently converted to Ang 
II in the lung. Ang II is a potent vasoactive peptide resulting in increased systemic 
resistance and blood pressure. Ang II also signals aldosterone release which 
acts on the kidneys to sequester fluid and sodium, thereby keeping the 
intravascular volume high, leading to further increases in blood pressure.99-102 
The entire system is counteracted by various mechanisms including alternative 
angiotensin peptide isoform signaling or compensatory signaling cascades, 
leading to potent vasodilation.12, 103-105 However, in pathologic conditions, the 
RAAS system has been known to drive increases in systemic blood pressure 
with resistance to counteracting mechanisms. 
 Sensitivity to Ang II is a hallmark of both PE and hypertension 
pathology.14, 100, 106-108 Alterations of the methyl-transferase activity within the cell 
leads to changes within the cytosine-rich segments of DNA within the promoter 
regions known as CpG islands. These alterations have been studied in 
hypertension. Some studies have shown alterations in the 5-methyl Cytosine 
(5mC) content in the promoter region of key RAAS components—Angiotensin 
converting enzyme and angiotensinogen.79, 109 While hypermethylation has been 
shown to regulate ACE expression and is associated with hypertension, 
hypomethylation of the angiotensinogen promoter was associated with a greater 
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expression angiotensinogen and was further driven by increases in salt intake. 
Furthermore, it has previously been reported that the angiotensin receptor gene 
is hypomethylated in a salt-sensitive rat progeny as early as the first week 
postpartum.79, 100, 106 Increased vascular sensitivity to Ang II has also been 
implicated in aortic, carotid, and small vessels in Ang II-exposed previously 
preeclamptic mouse and rat models.89, 100, 110 This could suggest an exaggerated 
RAAS response, as well as be evidence for the importance of methylation status 
in hypertension. 
Link between Inflammation and Intrauterine Stress 
Numerous studies have linked the pathologic activation of the RAAS to 
presence of an autoantibody against the AT1R (AT1-AA). While levels of AT1-AA 
are positively correlated with hypertension and renal damage in pregnancy, the 
mechanism of development of this antibody has not been elucidated. While 
pathologic activation of the AT1R has been linked to elevations TNF-alpha, IL-6, 
ET-124, 25, 27, 28, 31-33, 35, 36, 111, it is unclear if inflammation or epitope presentation is 
the stimulus for autoantibody production. Recent data has characterized the roles 
of a TNF superfamily member, LIGHT, and a glutamyltransferase, tissue 
transglutaminase (tTG) as necessary for production of AT1-AA.64 LIGHT-injected 
pregnant mice display autoantibody production via induction of a ε-(γ-glutamyl)-
lysine isopeptide dimerization in the AT1R. This modification is blocked by a 
specific tTG inhibitor, cystamine.112 This finding links the presence of acute 
inflammation via TNF activation, tTG, and the production of autoantibody in PE 
states (Luo R, under review, Hypertension). 
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Given these data, we present a novel mechanism for the transgenerational 
passage of epigenetic modifications and the role they play in the development of 
hypertension. We outline two necessary features integral for hypertension in a 
genetically homogenous mouse model. We hypothesize that hypertension 
requires: 
A. Exposure to intrauterine stress (i.e. preeclampsia stimulus) 
B. Subsequent exposure to provasoactive substance (i.e. angiotensin II) 
Through the data presented here, we show that intrauterine stress results in 
initial hypomethylation of the angiotensin II type I receptor promoter within CpG 
islands. Hypomethylation of this promoter leads to sensitivity to angiotensin II 
exposure and drives further hypomethylation of the AT1R promoter. This 
subsequently leads to increases in further AT1R expression and the failure to 
rectify the hypertensive insult. We also show that the pattern of hypomethylation 
can be transmitted through subsequent generations of progeny, leading to similar 
phenotypes and epigenetic genotypes in their progeny (Fig. 2-1). The study 
presented leads to tighter treatment of PE during the disease course and could 
lead to increased prediction of the PE and hypertension based on promoter 
methylation status. 
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 Figure 15. Hypothetical model of intrauterine stress and epigenetic modification. 
We posit a two-hit hypothesis as integral to development of multigenerational A-
HTN. In utero stress predisposes the fetus to hypomethylation of key RAAS 
genes, leading to their increased expression. Through mechanisms currently not 
understood, it has been shown that methylation patterns can be transmitted to 
subsequent generations. We believe that these methylation patterns, in tandem 
with exposure to environmental stress, will elicit a greater response, and, thus, 
cause features of hypertension. 
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Methods 
Mouse Model and Microosmotic Minipump Implantation 
Pregnant C57BL/6 mice were obtained on E13 of gestation (Harlan 
Laboratories; city). After a brief quarantine and acclimation period, baseline blood 
pressure was measured via tail-cuff methodology as previously described (Coda; 
Kent Scientific, Torrington, CT). Baseline mean systolic pressure was calculated 
from 20 repeated cycles of the CODA machine. After baseline blood pressure, 
female mice were injected retroorbitally with IgG isolated from normotensive (NT) 
and preeclamptic (PE) human patients as described in Irani, et al.24, 25 Mice were 
injected on E13/14 of gestation. Repeat blood pressure measurements were 
performed diurnally until E18. Mice were allowed to deliver producing generation 
II. Weaning occurred at post-parturition week three. Pups were subdivided and 
half of the litters were bred together to produce generation III. Remaining pups 
were aged for 26 weeks, during which time blood pressures were measured via 
tail-cuff methodology.  At 26 weeks, microosmotic minipumps (Alzet, Cupertino, 
CA) programmed to deliver 140 ng/kg/min of human angiotensin II (Sigma-
Aldrich, St. Louis, MO) were implanted in the dorsal region of the mice through a 
1 cm incision sub-cranially. Mice were monitored post-operatively for infection 
and recovery. Blood pressure was monitored via tail-cuff on minipump-implanted 
mice on D3, 7, 10, and 13 post-implantation. Mice were subsequently sacrificed 
on D14 for organ and histological analysis. Mice husbandry care was undertaken 
by Center for Laboratory Animal Medicine and Care (CLAMC) and Animal 
Welfare Protocol UT AWC-11-073/14-090. 
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Similar protocols were performed on generation III mice. 
Quantitative Real-Time PCR 
RNA was obtained from mouse renal tissue isolated and frozen in liquid 
nitrogen. RNA was reverse-transcribed into single-strand cDNA with use of the 
Quantitect reverse transcription kit (Qiagen, Venlo, Netherlands). cDNA was 
analyzed by qRT-PCR using SYBR green (Qiagen, Venlo, Netherlands) via 
specific primers to assess mRNA relative copy counts in the sample. Results 
were calculated using 2-ΔCt method using housekeeping gene for ratio 
comparison.62 
Western Blotting 
Presence of AT1R was confirmed by standard wet transfer methods. To 
confirm expression within the tissue, all tissues were cut to ~50 mg and 
homogenized in RIPA buffer with protease inhibitors (Santa Cruz 
Biotechnologies, Dallas, TX). Protein concentrations of tissue lysate were 
measured by BCA assay (Pierce, Grand Island, NY). To analyze by western 
blotting, 20-40 ug of protein were loaded onto 4-20% stacked SDS-PAGE gels 
(Bio-rad, Hercules, CA) and transferred onto PVDF-FL membranes (Millipore, 
Darmstadt, Germany). Membranes were probed with anti–mouse primary 
antibodies raised against AT1R in 1:500 dilutions (Santa Cruz Biotechnologies, 
Dallas, TX). An antibody to β-actin housekeeping gene(Sigma Aldrich, St. Louis, 
MO) was used as a loading control. Fluorescent conjugated secondary 
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antibodies were used for visualization of the membrane on LICOR imaging 
systems (LICOR, Lincoln, NE). 
Bisulfite gDNA Treatment and PCR Analysis 
To examine the methylation content of the renal AT1R promoter, bisulfite 
treatment and sequencing was utilized. gDNA was isolated from 50 mg flash-
frozen kidney sections utilizing a DNeasy kit and protocol (Qiagen, Venlo, 
Norway). gDNA was analyzed by spectrophotometry on a multiwell Take3 plate 
and synergyHT plate reader (Biotek, Winooski, VT) and normalized to 
concentration. Normalized gDNA was subsequently treated with bisulfite 
compound according to the EpiJet Bisulfite protocol (Thermo Scientific, Waltham, 
MA). To analyze promoter regions of the AT1R, the promoter sequence of AT1R 
was analyzed by MethPrimer software. Primers were designed to target expected 
CG-rich islands, based off of designated parameters.78, 89, 113 Primers to test the 
methylated and unmethylated regions were designed and subsequently used in 
qRT-PCR.  
Sequences of designed primers used were: 
5’3’ Methylated Forward AGTTTGGATTTGGAAGGGTATATC and Methylated 
Reverse AACTACCTAACGATCAACAACGAA 
5’3’ Unmethylated Forward GAGTTTGGATTTGGAAGGGTATATT and 
Unmethylated Reverse CAACTACCTAACAATCAACAACAAA.  
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CpG island methylation ratio was taken as ratio of unmethylated 
amplification:methylated amplification subtracting the background of amplification 
from non-bisulfite treated gDNA using the 2-ΔCt method. 
 
Crosslinked Chromatin Immunoprecipitation Assay 
Tissue extracted from mice treated with and without Ang II was flash-
frozen in liquid nitrogen. ~50 mg sections were cut from the kidney and 
underwent crosslinkage reaction using 1.5% formaldehyde in MeOH. Samples 
were homogenized, and chromatin was isolated from the kidney sections. A 
transcriptional predictive analysis examining promoter sequence homology found 
that c-Jun (AP-1) transcription factor has a 87% sequence homology with the 
AT1R promoter region. Based on these results, 25 µg crosslinked chromatin 
isolated from the kidney sections was incubated with c-Jun antibody (Abcam, 
Cambridge, UK) at a ratio of 3 µg antibody:25 ug chromatin on magnetic protein 
A/G beads overnight at 4 C. Chromatin samples were washed, eluted and de-
crosslinked according to protocol (ActiveMotif, Carlsbad, CA). Chromatin 
samples and input samples were analyzed by qRT-PCR as previously described 
above. 
Statistical Analysis 
All data were statistically analyzed with use of Graph Prism Pro v5.0, and 
the data were subjected to student’s t-test (paired and unpaired), two-way 
ANOVA, and turkey’s test, where appropriate. Accepted variance was 
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standardized to p < 0.05. Data were graphed on Graph Prism Pro v5.0 or 
SigmaPlot, where appropriate. 
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Results 
Intrauterine stress PE mouse model 
It is well accepted that intrauterine stress can have significant 
developmental ramifications to affected fetuses. Such developmental 
abnormalities can be observed within the renal, neurological, and, most 
significantly, cardiovascular system. Our study utilizes an established model of 
intrauterine and maternal stress by using an adoptive transfer model of human 
AT1-AA isolated from PE patients. Previous models have demonstrated that 
isolated AT1-AA injected into pregnant mice induces key features of PE including 
hypertension and renal damage as well as features of intrauterine growth 
restriction in the fetal milieu.24, 25, 27, 28 Our model uses these features of PE to 
represent intrauterine stress and developmental delay.  
  
71 
 
  
Figure 16. Model of adoptive transfer of IgG to pregnant mice on embryonic day 
13/14 precipitates PE features. A transgenerational mating scheme was developed 
to produce Generation I, II, and III. 
  
Our experimental model involves isolation of IgG from both normotensive 
mothers (NT-IgG) to serve as control and IgG from PE mothers (PE-IgG). IgG 
was injected into mice on embryonic day 13 and 14 of gestation. Pups 
(generation II) were born to affected and control mothers. Generation II mice 
were monitored for growth and blood pressure. Generation II mice were interbred 
to produce generation III mice and these were monitored for physiologic 
characteristics in the same manner as generation.  
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 After parturition, baseline characteristics were measured in the pups and 
examined for significant phenotypic differences (Fig 2-2). To confirm the 
presence of true in utero stress and PE features, we analyzed the AT1-AA and 
NT-IgG injected mice. We discovered that pregnant mice injected with AT1-AA 
had significant hypertension and renal damage, as reflected by microalbuminuria, 
which resolved in the postpartum period (Fig. 2-3). Features of PE in the mouse 
model resolved by postpartum day 10, corresponding to approximately week 12 
of human postpartum periods, similar to the disappearance of features in human 
PE pregnancies. 
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Figure 17. Mean systolic pressure and microalbuminuria are significantly 
increased in PE-IgG injected generation I mice but these features resolve in 
the postpartum period. 
(Left) In PE-IgG injected dams (Generation I), mean systolic pressure was 
significantly increased in the antepartum period. This increased systolic pressure 
resolved in the 10-day postpartum period, similar to human PE chronology. n = 4-
5; * = p < 0.05. (Right) Similarly, microalbuminuria was significantly increased in 
PE-IgG injected dams antepartum, but this increase in microalbuminuria was 
attenuated in the postpartum period. n = 4-5; * = p < 0.05.  
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Mice exposed to intrauterine stress demonstrate no phenotypic abnormalities  
One of the key hallmark features of intrauterine stress is the presence of 
intrauterine growth restriction and, possibly, fetal abnormality. It is well-
established that intrauterine growth restriction results in features of prematurity 
which often result in developmental delay organ-system specific abnormality. We 
observed the pups born to the in utero stressed pregnancy and subsequent 
generations. Because literature has noted a pup and litter size decrease in those 
pregnancies affected by AT1-AA, we monitored the growth curve for significant 
difference between the AT1-AA and control pups. Expectedly, we observed a 
difference in male/female weights, but no significant difference in the growth 
rates of pups born to AT1-AA affected mice or to subsequent pregnancies (Table 
3).  
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Table 3. Mouse growth curve and weight characteristics (g). 
 
 
  
 
Male Female 
 
Week 4 Week 8 Week 4 Week 8 
 
NT-IgG PE-IgG NT-IgG PE-IgG NT-IgG PE-IgG NT-IgG PE-IgG 
Generation II 
19.1 ± 
1.01 
18.06 ± 
1.33 
19.73 ± 
1.17 
19.60 ± 
2.00 
14.26 ± 
1.10 
17.06 ± 
3.23  
19.93 ± 
3.38 
19.91 ± 
1.89 
 Generation III 
17.76 ±  
0.28 
19.46 ± 
1.3 
21.05 ± 
1.4 
20.12 ± 
0.57 
17.1 ± 
0.78 
17.9 ± 
1.27  
18.99 ± 
4.2 
20.56 ± 
1.05 
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 Noting that the growth curves and litter sizes of the mice were similar, we 
investigated whether mice born to affected pregnant mothers had alterations of 
inflammatory and RAAS components as has been demonstrated in offspring of 
stressed pregnancies. To determine this feature, we examined mRNA values of 
various inflammatory markers and RAAS components via qRT-PCR from cDNA 
isolated from the kidney of generation II mice. Through a qRT-PCR array of 
kidney cDNA isolated after pup delivery, we found no difference in renin, 
angiotensin converting enzyme, angiotensin II type II receptor, nor aldosterone 
within the RAAS. We also found no difference in transcript levels of commonly 
deranged inflammatory and vascular signaling components such as tumor 
necrosis factor-alpha, endothelin-1, endothelin receptors A/B, nor endothelin 
converting enzyme. These data indicate pups born to in utero stressed 
environments experience no baseline derangements in terms of developmental 
patterning, nor do they experience alterations within their various vascular and 
inflammatory signaling pathways. However, these data do not completely explain 
the increased incidence of adult-onset hypertension seen in adult progeny of in 
utero stressed pregnancies in the absence of genetic factors. To reveal this 
feature, we decided to investigate each generation of progeny with a pro-
vasoactive stimulus during the progeny adult period. 
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Low-dose Angiotensin II (Ang II) results in significant systolic pressure increase 
in progeny born exposed to in utero stress 
While the data indicate that progeny born after exposure to in utero stress 
are phenotypically normal, observational clinical literature has noted a significant 
prevalence in adult-onset hypertension in the progeny which have been exposed 
to intrauterine stress. To test this observation in our mouse model, we aged 
progeny born from exposure to AT1-AA for 24 weeks before exposing them to a 
low-dosage of Ang II (140 ng/kg/min)114 (Fig. 2-4).  
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Figure 18. Schema of 24 week aging mouse model followed by low-dosage 
Ang II infusion. Mean systolic pressure was monitored at regular intervals 
during the experiment. 
Mice born to both PE-IgG and NT-IgG injected mothers were aged for six months 
and implanted with an osmostic minipump containing a low-dosage of Ang II (140 
ng/kg/min). Blood pressure was measured after pump implantation on days 3, 7, 
10, and 13. This same schema was used in the subsequent generation to 
determine if this phenomena travels transgenerationally.  
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Low-dosage Ang II is not thought to be a model of intrinsic renal damage, 
however, the low-dosage is adequate to demonstrate an increased sensitivity to 
a provasoactive stimulus. To verify that the aging process induced no significant 
effect on mean systolic pressure, baseline blood pressures were taken at week 
12 of aging. We demonstrated that mean systolic pressure is not affected by 
aging at this early timepoint (Fig. 2-5).  
 
Figure19. Mean systolic blood pressure measured at week 12 indicated no 
significant difference in mean systolic pressure. 
Generation II mice showed no significant difference in mean systolic blood 
pressure at week 12 after delivery. n = 6 mice 
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To test Ang II sensitivity, microosmotic minipumps containing infusion dosages of 
140 ng/kg/min were dorsally implanted into mice born after exposure to 
intrauterine stress as well as control mice. During the period of implantation, 
mean systolic pressure was monitored. Mice born from exposure to intrauterine 
stressed environments show a significantly earlier elevation, as well as a 
sustained elevation of mean systolic blood pressure as compared to control pups 
(Fig. 2-6).  
 
 
Figure 20.  Low-dose Ang II resulted in more significant and earlier 
elevation in mean systolic pressure in generation II mice. 
Implantation of a microosmotic minipump infusing a low-dosage of Ang II 
demonstrated that generation II mice born to PE-IgG infused dams had an earlier 
and larger increase in mean systolic pressure from baseline than did mice born 
to control dams. * = p < 0.05; 4-6 mice/group.  
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These data indicate that pups born exposed to intrauterine stress lack 
mechanisms to rectify increases in vascular tone. Moreover, to test that these 
features are also present in subsequent generations, generation II is interbred to 
produce generation III. 
To test similar features in generation III, the same experimental plan was 
followed, as previously described. Generation III mice were aged and measured 
at midpoint through the aging period to determine if age had a significant effect 
on baseline blood pressure. Baseline blood pressure measurements taken at 
week 12 show no difference in mean systolic pressure between interbred 
generation III mice (Fig 2-7).  
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 Figure 21. Generation III mice showed no significant difference in mean 
systolic pressure at week 12. 
Similar to generation II, generation III mice show no difference in mean systolic 
pressure at week 12. n = 6 mice  
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Thus, at week 24 mice were implanted with a microosmotic minipump with a 
dosage containing 140 ng/kg/min Ang II for infusion. Similar to generation II, mice 
exposed to intrauterine stressed environments in a prior generation experience 
an earlier and more significant increase in mean systolic pressure from baseline 
after Ang II challenge than normal control mice (Fig. 2-8). 
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Figure 22. Generation III mice experienced a more significant and earlier 
increase in mean systolic pressure versus control mice. 
Similar to generation II, generation III mice born to the lineage of stressed 
pregnancies and subsequently exposed to Ang II have a significantly earlier and 
sustained elevation of mean systolic pressure than control mice. * = p < 0.05; n = 
6 mice/group  
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These data indicate an interesting paradox—intrauterine stress in one generation 
can prime future generations for increases in mean systolic pressure, given a 
stressor. This increase in hypertension is difficult for the organism to rectify. 
However, the mechanisms behind this increase in blood pressure and its 
presence in subsequent generations has not been characterized. 
Epigenetic modifications of the AT1R predispose increased AT1R expression 
levels and hypertension 
With a low-dosage of Ang II, we witnessed an increase in mean systolic 
pressure in animals exposed to intrauterine stress. We witnessed this feature 
propagating from the second to the third generation. However, the molecular 
mechanism behind this increased hypertension is poorly characterized.  
It is well-accepted in other research fields that epigenetic modifications are 
responsible for features that are outside of the scope of genetic mutation. It is 
thought that epigenetic mutations are responsible for many disease processes in 
the fields of cancer and neurological conditions. Utilizing a genetically 
homogenous mouse population, we are able to characterize epigenetic changes 
in mice that examine changes to expression apart from genetic alteration. 
To examine epigenetic changes within our mouse progeny, we utilized a 
bisulfite PCR screening to examine the epigenetic modifications of promoter 
regions of the AT1R. Because Ang II was used as the stimulus for the vasoactive 
challenge, and in the absence of alterations of other RAAS and inflammatory 
signaling factors, we looked to the AT1R as a likely candidate for modifications. 
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We designed a sequence of primer sets to test the methylation content of CG-
rich sequences within the AT1R promoter region. This common technique 
assesses the methylation content of cytosine residues within the gene promoter 
region. Bisulfite sequencing revealed a significant hypomethylation of the 
promoter region between 597-714 base pairs upstream from the transcription 
start site in mice born from intrauterine stressed environments. Furthermore, this 
hypomethylation is exacerbated by Ang II treatment. This finding suggests that 
methylation patterns are imprinted during the intrauterine period and exposure to 
Ang II results in further hypomethylation (Fig. 2-9).  
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 Figure 23. The AT1R promoter was hypomethylated in utero and further 
hypomethylated with exposure to Ang II. 
(Top panel) Five CpG primer pairs were designed based on promoter 
sequencing prediction. Only a region between 597-714 bp upstream from the 
transcription start site showed amplification. (Bottom panel) Bisulfite sequencing 
revealed that the AT1R promoter region in generation II isolated renal tissue is 
initially hypomethylated in utero prior to Ang II challenge. Hypomethylation is 
further exacerbated by Ang II challenge. * = p < 0.05; 3-4 renal samples/group  
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This pattern of hypomethylation has significant effects on AT1R expression. 
AT1R expression is increased in pups exposed to intrauterine stress, but, this 
difference is exacerbated by treatment with Ang II. This expression data was 
confirmed by qRT-PCR and immunoblotting data from kidney cDNA and 
membrane receptor isolation, respectively (Fig. 2-10). 
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(Top panel) AT1R mRNA expression in generation II indicated that expression of 
AT1R initially is elevated in utero but is exacerbated by treatment with Ang II. 
This expression level is confirmed by qRT-PCR. (Bottom panel) Representative 
immunoblotting revealed that Ang II treatment increased expression levels of 
AT1R from basal levels. * = p < 0.05; n = 3-4 renal sections/group 
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Figure 24. AT1R expression increased with Ang II exposure as confirmed by 
qRT-PCR and immunoblotting. 
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Extending this hypothesis to the subsequent generations, we investigated 
whether exposure to intrauterine stress had an effect the third generation. Thus, 
we performed similar experiments on the third generation to test if the animals 
had the same methylation patterns as the second generation. Bisulfite 
sequencing showed that the AT1R promoter region was hypomethylated in the 
same region as the second generation animals. Furthermore, in the presence of 
Ang II stimulus, generation III animals exposed in their previous generation 
experienced more significant hypomethylation in a key CG rich region as 
opposed to control animals. Examining expression of AT1R, we witnessed a 
higher expression of AT1R in generation III animals exposed to in utero stress. 
This was exacerbated once again by exposure to Ang II stimulus (Fig. 2-11). 
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 Figure 25. AT1R specific methylation was decreased and AT1R expression 
is increased as confirmed by qRT-PCR and immunoblotting in generation II 
mice. 
(Top left panel) Mice born to a lineage of in utero stress (generation III) display a 
similar pattern of methylation as generation II. CpG island methylation is 
decreased in utero prior to Ang II challenge, but displays a further decrease with 
low-dose Ang II treatment. (Top right panel) Decreases in methylation precipitate 
an increase in AT1R expression evident after treatment with Ang II as confirmed 
by qRT-PCR. (Bottom panel) AT1R expression is elevated in mice born to in 
utero stressed lineages. The AT1R expression is further exacerbated by 
treatment with Ang II as confirmed by immunoblotting. * = p < 0.05 
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 These data suggest a key finding in the pathogenesis of vascular disorder 
and the heritability of these features. We noted that sensitivity to a stimulus is 
determined by amount of hypomethylation of the AT1R promoter region. 
Furthermore, provasoactive stimulus causes significant hypomethylation of the 
AT1R promoter. This hypomethylation activity has significant effects on gene 
expression. Finally, these data suggest that all of these features can pass 
through generations, implying that in utero insults in one generation can affect 
development of future generations. 
Hypomethylation of AT1R promoter region results in AP-1 transcriptional 
activation 
As reported in other literature, promoter modification can affect 
transcriptional gene activation or repression by influencing the binding affinity of 
transcription factors at key sites. To assess the degree of transcriptional binding 
affinity, chromatin binding immunoprecipitation assays (ChIP) is frequently used. 
These assays determine the binding efficiency of transcription factors in a 
promoter sequence. Because of the observation of differential promoter 
methylation in our mouse model, we decided to test the binding efficiency of 
transcription factors in the hypomethylated promoter region.  
Prior to designing targets for ChIP assay, we performed a blinded 
sequence analysis on the hypomethylated promoter region. By BLAST analysis, 
we determined that the c-Jun (AP-1) transcription factor had a predicted 88% 
sequence homology with the hypomethylated AT1R promoter region. 
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Interestingly, AP-1 is extensively involved in growth factor, vascular factor, and 
inflammatory factor signaling. Therefore, we decided to test the transcriptional 
affinity of AP-1 with hypomethylated AT1R promoter sequences. Utilizing 
crosslinking ChIP assays with chromatin isolated from the kidney of the 
generation I mice, we found an increase in AP-1 binding to the hypomethylated 
region of the AT1R prior to Ang II treatment. However, after Ang II treatment, we 
observed a 2-fold increase in AP-1 activation and binding in the AT1R promoter 
region. This indicates significant activation of AP-1 and a potential explanation 
behind the increased expression of AT1R both in utero and after provasoactive 
stimulus. We further extend these findings to generation III. Chromatin was 
isolated from kidney tissue of interbred animals prior to treatment with Ang II and 
subsequent to treatment. 
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 Figure 26. AP-1 transcription factor binding affinity is increased in 
hypomethylated AT1R promoter regions. 
(Top panel) Transcription factor prediction by PROMO analysis showed an 88% 
sequence homology with a hypomethylated promoter sequence in the AT1R 
promoter. (Left panel) XChIP assays crosslinking AP-1 transcription factor to 
chromatin segments found greater AP-1 binding and amplification of 
hypomethylation AT1R promoter regions in generation II after Ang II treatment in 
pups exposed to in utero stress. (Right panel) In pups born from lineages of in 
utero stress (generation III), exposure to Ang II increases the binding of AP-1 
transcription factor and subsequent amplification of specific hypomethylated 
sequences of the AT1R promoter.  
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Discussion 
Presented here is the first mouse model to recapitulate the features of 
adult-onset hypertension when primed with an in utero stress. Genetically 
homogenous cohorts of mice were given IgG isolated from human patient 
cohorts to represent a PE pregnant model or normal pregnancy. PE is associated 
with hypertension and renal damage both in patients and in generation I of this 
mouse model. Similar to patients, PE features of hypertension and 
microalbuminuria resolved in the murine postpartum period. In generation II, after 
the mice were aged for 24 weeks and exposed to a vasoactive peptide (Ang II), 
mice born from intrauterine stressed pregnancies were more susceptible to 
hypertensive features. Mechanistically, consistent with current literature in 
hypertensive disorders, we witnessed an activation of the RAAS with increased 
sensitivity to Ang II stimuli. Interestingly, these data presented here offer a 
unique two-hit mechanism to demonstrate how in utero stress precipitates 
hypertensive feature in progeny. We established that aberrant promoter 
methylation patterns occurring during intrauterine stressed environments can 
predispose an organism to increased transcription of the AT1R gene and 
receptor. This aberrant methylation pattern and increased transcription of RAAS 
components increases sensitivity to environmental stimuli, and thus, increases 
the chance for the organism to develop adult-onset hypertension. This new 
paradigm stresses the importance of the intrauterine milieu as causative for 
future development of disease in progeny. While the mechanism underlying 
promoter methylation pattern changes is not addressed in this work, our data is 
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consistent with other studies which also demonstrate decreased total methylation 
in PE states.  
In addition to methylation changes in direct progeny born from in utero 
stressed environments, we also show that subsequent generations exhibit the 
same aberrant methylation patterns within the RAAS. Previous studies have 
demonstrated that epigenetic promoter methylation patterns can be transmitted 
between generations and imprinted onto progeny DNA. Thus, methylation 
patterns can affect subsequent generations genetic expression outside of genetic 
modifications. Our data demonstrate these similar features. Generation III, 
exhibits similarly decreased promoter methylation as the previous generation. 
Therefore, similar features of hypertension exist within this generation upon 
challenge with a vasoactive peptide.  
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 Figure 27. Working model of transgenerational passage of epigenetic 
features. 
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 While we observe this two-hit hypothesis in our mouse model, we have 
not investigated the mechanism behind the alteration of epigenetic patterning in 
progeny nor the passage from one generation to the next. Some studies have 
demonstrated the importance of S-adenosyl methionine and methyl transferases 
as necessary for epigenetic alterations on the histone or promoter transcriptional 
level. Studies have indicated that intracellular stress modulates the activity of 
methyl transferase and the recycling of S-adenosyl homocysteine to S-adenosyl 
methionine. Therefore, stressed conditions have the ability to decrease 
methylated DNA within the promoter. Depending on the modification, this can 
have activating or inhibiting consequences for genetic transcription. Future 
studies will address how this pathway is modulated in times of intracellular or in 
utero stress. These studies will have important ramifications for risk stratification 
based on pregnancy status. 
This study investigates the role of PE in the pathogenesis of adult-onset 
hypertension. We posit a unique combination of decreased AT1R methylation 
combined with increased expression of AT1R as instrumental in the activation of 
the RAAS. Previous clinical data has implicated PE as an important risk factor 
future cardiovascular risk. We also know that progeny born from intrauterine 
stressed pregnancies also have increased cardiovascular risk. Based off of these 
data, asking for familial incidence of PE may help us stratify a patient’s risk to 
develop hypertension, stroke, or cardiovascular death. Furthermore, our study 
also investigates a specific mechanism of upregulation of the AT1R. By 
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assessing a patient’s promoter methylation patterns, clinicians would have a 
picture of which messengers within the RAAS are altered. With further clinical 
and epidemiological study, our data may lead to more personalized treatment of 
hypertensive disorder and proper cardiovascular risk stratification.  
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CHAPTER III: CONCLUSIONS AND FUTURE DIRECTIONS 
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Disorders of hypertension during pregnancy present a unique challenge 
as a healthcare issue. Decades of research have provided insights into the 
pathogenesis of the disease; however, no definitive molecular process has 
outlined the disease in totality. Furthermore, the lack of definitive mechanism has 
also led to a lack of appropriate diagnostic tests to assess a mother’s chance to 
develop preeclampsia or other hypertensive disorder of pregnancy. Finally, due 
to the length of prospective studies, we are unaware of the effect that in utero 
stress has on generations of progeny. Because of these problems, research in 
the field of preeclampsia is vital to our understanding of the disease 
pathogenesis and pregnancy, as a whole. 
The studies presented here provide valuable insight into the pathogenesis 
of PE as well as posit potential therapeutic targets and diagnostic exams to treat 
and estimate a mother’s risk for disease development. The data confirming the 
interplay between CRP, NKB and phosphocholine transferase, being well-known 
possible factors inciting vascular damage, examines a new pathogenic 
mechanism for PE. Moreover, the CRP-NKB-phosphocholine complex provides a 
novel therapeutic target and potential diagnostic panel to predict and diagnose 
PE prior to onset. Furthermore, the transgenerational mouse model is one of the 
first studies to address the influence of in utero stress as a potential mechanism 
of vascular genetic expression in a homogenous genetic population. The 
implication for PE priming vascular damage through subsequent generations 
provides an opportunity for progeny testing for hypertension risk. 
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The roles of CRP and NKB in the pathogenesis of PE have been 
extensively hypothesized in earlier literature. However, this report was the first to 
indicate that CRP acts as more than a nonspecific inflammatory mediator. We 
present evidence that CRP can combine with a posttranslationally modified and 
phosphocholinated NKB to activate the NK3R, a receptor instrumental in 
hypertension. These data novelly indicate that the placenta was a contributory 
source of CRP, and this excess production was instrumental in PE 
symptomology. The placenta is vital in the production of PE features and key to 
therapeutics. 
In recent decades, the placental-fetal environment has become a potential 
target for study in the heritability of PE and hypertensive disorders. While much 
research has been dedicated to investigating genetic causes behind 
hypertension, other mechanisms have been less studied. Epigenetic 
mechanisms of disease are thought to underlie many pathogenic processes. 
Elucidation of epigenetic modifications could serve as prediction for adult-onset 
hypertension. Additionally, epigenetic screening could lead to targeted therapy 
for hypertensive disorder. By characterizing the epigenetic modification on 
various promoters, we may be better to able screen for upregulated genes and 
develop a targeted therapeutic to treat refractory hypertensive patients. 
Furthermore, by studying in utero stress as it propagates through generations, 
we can counsel women to avoid potential stressors, as they may affect their 
intrauterine environment, and, ultimately their progeny. 
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The novel data presented here posit a holistic view of preeclampsia, 
hypertension, and hypertensive disorders of pregnancy. First, we have 
demonstrated that acute inflammation and kinin signaling are integral in the 
pathogenesis of PE. The molecular complex formation of CRP joining with post-
translationally modified NKB is essential to activation of the NK3R and production 
of PE features. More importantly, the placenta is required for CRP-induced PE 
features, as CRP has no effect in non-pregnant animals in the absence of 
inflammatory stimulus. Inflammatory stress and activation of the kinin signaling 
system leads to intrauterine stress, creating a malicious cycle harming the 
mother and fetus. The fact that intrauterine stress has been noted as a potential 
cause of developmental patterning dysfunction is an important clinical finding that 
we have translated into our mouse model. We have demonstrated that acute 
inflammation in the form of TNF-alpha superfamily members can induce 
elevations of pathogenic autoantibodies against the AT1R. The presence of AT1-
AA in maternal circulation is positively correlated with PE features, IUGR, and, 
thus, intrauterine stress. Through a multigenerational mouse model, we have 
shown that intrauterine stress can initiate hypomethylation in the AT1R promoter, 
and prime the developing fetus to development of hypertension. Further 
exposure to a stress increases risk of hypertension development. Without 
compensatory mechanisms, progeny are more sensitive to stimuli, and, thus, 
develop hypertension more than progeny born to normal pregnancies. More 
significantly, demehtyalted promoter regions are passed to future generations, 
thus, predisposing a fetus in the absence of a direct fetal stress. These findings, 
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in tandem, present numerous opportunities for preclinical diagnostics and 
targeted therapy (Fig. 3-1). 
 
Figure 28. Working model linking intrauterine stress to transgenerational 
programming. 
CRP-PC-NKB activation of the NK3R leads to pathogenic features of PE—
hypertension, renal damage, and sFlt-1 expression. The contribution of these to 
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intrauterine stress can prime a developing fetus with hypomethylation of the 
RAAS system and risk of hypertension after a late life exposure to environmental 
stimulus. 
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Future Directions 
The data presented here reveal a comprehensive picture of the pathogenesis of 
PE as well as offer explanations for transgenerational feature propagation. 
However, even with intensive research efforts, neither the totality of PE 
pathogenesis has not been elucidated, nor is research closer to finding effective 
therapeutics and diagnostic assays. One significant finding to further investigate 
is the value of assessing CRP and NKB prior to 20 weeks of gestation in our 
pregnant cohort. Currently, human sera and plasma samples from the Combined 
Antioxidant and Preeclampsia Prediction Study are available in various time 
points both ante- and post-partum. These samples would be a valuable tool to 
develop and test a diagnostic predictive clinical panel to predict the onset of PE. 
Furthermore, this panel could become part of a woman’s routine clinical prenatal 
exam.  
In addition to PE prediction, our study also addressed fetal developmental 
outcomes. We have demonstrated that epigenetic promoter modifications are 
conserved throughout generation. According to available literature, peripheral 
blood mononuclear cells provide an excellent tool for examining the 
methylation/epigenetic portrait of a patient’s cells. By further characterizing the 
methylation aberration within the patient’s cells, we would better be able to see 
the effect of intrauterine stress on progeny, and estimate a conferred risk to 
future generations. Furthermore, utilizing identified epigenetic markers, targeted 
treatment options are more effective. 
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